Supplement Shows Promise For Improving Cancer-Related Cognitive Impairment

TL;DR

Before you orderOffer from Amazon

Get oils, diffusers and self-care delivered free with Prime

• Fast, free delivery on millions of items
• Prime Video, Amazon Music and more included
• Member-only deals all year

Start your free Prime trial →Free trial for eligible customers · Cancel anytime

As an affiliate, we earn on qualifying purchases.Hide

A small single-arm study found improved self-reported cognitive function among 16 breast cancer survivors who completed eight weeks of oxaloacetate treatment. The findings are preliminary: there was no control group, and a randomized, placebo-controlled study is expected to begin enrolling before the end of 2026.

A small study of breast cancer survivors found that self-reported cognitive function improved after eight weeks of the supplement oxaloacetate, with all 16 participants who completed treatment showing improvement on the primary assessment. The uncontrolled study cannot establish that oxaloacetate caused the change, and researchers say a randomized, placebo-controlled trial is expected to begin enrollment before the end of 2026.

The study enrolled 18 breast cancer survivors who were one to five years past cancer treatment and had documented cognitive impairment. Participants took 500 milligrams of oxaloacetate twice daily for eight weeks; 16 completed the study. The main outcome was perceived cognitive impairment measured with the FACT-Cog PCI assessment.

Among those who completed the study, the mean FACT-Cog PCI score rose from 29.1 at baseline to 55.5 after eight weeks. The report said improvement was apparent at four weeks and generally increased over the following four weeks. The mean score moved from the impaired range into the normal range, according to the study findings. Neuropsychological tests also showed improvement in executive function and processing speed.

Researchers also reported improvement in fatigue and physical functioning, with a trend toward improvement in insomnia. Treatment was generally well tolerated, though reported gastrointestinal effects included indigestion, bloating, constipation and diarrhea. Two of the 18 enrolled participants did not complete the study; the supplied report does not give further details about their reasons for leaving.

A Potential Option for Post-Treatment Brain Fog

Cancer-related cognitive impairment can affect memory, attention, processing speed and daily functioning after cancer treatment. The study’s reported changes matter because people experiencing these symptoms may have limited medication options, and the intervention is distinct from approaches often examined in earlier research, such as exercise and strategies addressing anxiety, depression or related concerns.

Still, the findings are an early signal rather than evidence that oxaloacetate works. The results came from a small group without a comparison arm, and the main measure captured participants’ perceptions of their cognitive function. Without a placebo group, researchers cannot separate a possible treatment effect from factors such as expectations, changes over time or other influences. The planned trial will be needed to test whether the improvement exceeds what would occur without the supplement.

How Researchers Reached the Trial

Oxaloacetate is a naturally occurring human metabolite involved in cellular energy production and the regulation of glutamate, a neurotransmitter associated with cognitive function. Prior clinical research has examined the compound for cognition and fatigue, including a small randomized study involving people with long COVID. Those studies provided background for testing oxaloacetate in cancer survivors, but they do not establish its effectiveness for cancer-related cognitive impairment.

The study authors used an initial two-step design. They set a four-point improvement on the FACT-Cog PCI as the threshold for a positive outcome among the first nine participants; preliminary results showed a 27-point improvement. The authors said those early results led them to revise the study so it could be completed with a smaller overall sample and support development of a randomized trial. The report was published in JCO Oncology Advances.

The cause of cancer-related cognitive impairment is not fully understood. The report notes that the condition has been studied extensively among breast cancer survivors and that some chemotherapy agents can cross the blood-brain barrier and have recognized neurotoxic effects. Cognitive symptoms are also reported in people treated for other cancers, so the issue is not limited to breast cancer.

“These early findings give us a strong reason to continue studying oxaloacetate as a potential approach for managing cognitive problems after breast cancer treatment.”

— Patricia Ganz, MD, of UCLA Health, in a press release

What the Small Study Cannot Show

The study had no placebo or untreated comparison group, and only 16 participants completed treatment. That limits conclusions about whether oxaloacetate caused the improvement and whether the results would hold in a larger, more varied group of patients. The reported gains in self-perceived cognition also need to be assessed alongside objective testing and a comparison group in further research.

The supplied report does not provide enough detail to determine why two enrolled participants did not complete the study, or to fully characterize the frequency and severity of adverse effects. It also does not establish how long any improvements might last after treatment ends, which patients are most likely to benefit, or whether the findings apply to survivors of cancers other than breast cancer. The study’s results do not establish oxaloacetate as a proven treatment for cognitive impairment.

A Placebo-Controlled Trial Is Planned

A randomized, placebo-controlled phase II study is expected to begin enrollment before the end of 2026, according to the report. By comparing oxaloacetate with placebo, researchers can better determine whether changes in cognition, fatigue and physical functioning are linked to the supplement rather than to other factors.

Details about the planned trial, including its final enrollment target, eligibility rules, study length and outcome measures, were not provided in the source material. Until results from controlled research are available, the eight-week findings should be treated as preliminary. People considering supplements during or after cancer treatment should discuss them with their healthcare team, particularly because this study does not establish long-term safety or effectiveness.

Key Questions

What did the oxaloacetate study find?

Among 16 breast cancer survivors who completed the study, the mean self-reported FACT-Cog PCI score rose from 29.1 to 55.5 after eight weeks. Researchers also reported improvements in fatigue and physical functioning. Because the study had no control group, it cannot show that oxaloacetate caused the changes.

How was oxaloacetate taken in the study?

Participants took 500 milligrams twice daily for eight weeks. The study enrolled 18 people, and 16 completed it.

Does this study prove oxaloacetate treats cancer-related cognitive impairment?

No. It was a small, uncontrolled study. A randomized, placebo-controlled trial is needed to test whether oxaloacetate provides benefits beyond placebo or other influences.

What side effects were reported?

The report describes the treatment as generally well tolerated and lists gastrointestinal symptoms, including indigestion, bloating, constipation and diarrhea. The available information does not fully detail how often or how severely these effects occurred.

When will the next study begin?

A phase II placebo-controlled study is expected to begin enrollment before the end of 2026, according to the report. Further details about its design and enrollment were not provided.

Source: rss